Telomeres are tandem nucleotide repeats at the ends of chromosomes essential for maintenance of chromosome stability. Leukocyte telomere length (LTL) has been suggested as a biomarker of cancer prognosis ([@bib13]). A recent meta-analysis found short LTL to be associated with poorer overall cancer survival, although substantial heterogeneity was apparent across cancer types ([@bib13]). In the case of renal cell carcinoma (RCC), the most fatal urologic malignancy, two small studies have investigated LTL and survival, with conflicting findings. A study of 83 clear cell RCC cases, using blood collected after diagnosis, found longer LTL to be associated with poorer survival ([@bib9]). Conversely, in a study of 59 kidney cancer cases from a population cohort with pre-diagnostic samples, shorter LTL was non-significantly associated with worse survival ([@bib10]).

To clarify the relationship between LTL and RCC prognosis, we conducted an investigation among 684 cases from a US case--control study and 241 cases from the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.

Materials and methods
=====================

Methods of both studies have been described previously ([@bib4], [@bib5]). The US Kidney Cancer Study (USKC) is a population-based case--control study of Caucasians and African Americans conducted in Detroit, MI and Chicago, IL. In Detroit, potentially eligible cases diagnosed between 1 February 2002 and 31 July 2007 were identified through the Metropolitan Detroit Cancer Surveillance System, a member of the NCI Surveillance, Epidemiology, and End Results (SEER) Program. The median time between diagnosis and blood sample collection was approximately 4 months (range, 1--47 months). Deoxyribonucleic acid (DNA) was extracted from whole blood or buffy coat using Qiagen kits (Qiagen Inc., Valencia, CA, USA), and relative LTL was measured by quantitative PCR ([@bib4]). Telomere repeat (T) and single gene (S) copy numbers were measured in each sample and adjusted in comparison to standard reference DNA; the standardised T/S ratio characterises relative telomere length. Blinded duplicate samples from 59 participants were interspersed among test samples for quality control; the resulting data suggested high assay reproducibility, with a coefficient of variation (CV) of 9.9%. The mean T/S ratio among controls was 0.87 (standard deviation (s.d.) 0.20). The analyses reported herein are restricted to Detroit cases, for whom vital status and underlying cause of death had been ascertained through 31 December 2012 via SEER linkage ([@bib7]).

Prostate, lung, colorectal, and ovarian cancer screening trial is a large multi-centre cancer screening trial, the methods of which have been described ([@bib3]). Leukocyte telomere length measurements were performed using pre-diagnostic specimens from 241 RCC cases who participated in PLCO as part of a previous nested case--control study ([@bib5]). Deoxyribonucleic acid was extracted from buffy coat using Qiagen kits (*n*=209) or was previously extracted (*n*=32). Leukocyte telomere length was measured using monochrome multiplex PCR. The CV from 36 blinded quality control samples distributed evenly across nine plates was 5.9%. The mean T/S ratio among controls was 1.44 (s.d.: 0.89). Cases were followed for vital status and underlying cause of death via linkage with the National Death Index through 31 December 2008.

Leukocyte telomere length was measured in different laboratories using different standard reference DNA. Thus, the two studies were analysed separately, with categorisations of LTL based on study-specific quartiles. We used multivariable Cox proportional hazards models to compute hazard ratios (HRs) and 95% confidence intervals (CIs) relating disease-specific survival to categories of LTL while adjusting for age, sex, race, study center (PLCO only), body mass index, smoking status, hypertension, diabetes, source of DNA, and education. Data from the USKC study, which unlike PLCO had collected information on tumour characteristics, were further adjusted for histology, stage, treatment, grade, and tumour size. All analyses were conducted using SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA). The proportional hazards assumption was tested using an interaction term for LTL and survival time, which was not significant. Study-specific results were combined by meta-analysis using a random effects model.

Both studies were approved by Institutional Review Boards at collaborating institutions, and written informed consent was obtained from all participants.

Results
=======

Characteristics of cases are presented in [Table 1](#tbl1){ref-type="table"}. Ninety-six and 62 RCC-related deaths were ascertained among USKC and PLCO cases, respectively. The study-specific associations between LTL and RCC survival are summarised in [Table 2](#tbl2){ref-type="table"}. Shorter LTL was associated with poorer disease-specific survival in both USKC (shortest *vs* longest quartile: HR: 2.3, 95% CI: 1.2--4.4; *P*~trend~=0.02) and PLCO (HR: 2.4, 95% CI: 1.0--5.4; *P*~trend~=0.04). The association between LTL and RCC survival was in the same direction when stratified by median time from blood collection to diagnosis, but a statistically significant trend was only observed among cases diagnosed \>6.5 years after blood collection ([Table 2](#tbl2){ref-type="table"}). Leukocyte telomere length was not associated with death from other causes in either study (USKC, HR: 0.8, 95% CI: 0.4--1.4; *P*~trend~=0.91; PLCO, HR: 1.4, 95% CI: 0.5--3.7; *P*~trend~=0.60). Restricting analyses to clear cell RCC, or to cases with DNA extracted from buffy coat in PLCO or whole blood in USKC, or to USKC cases who had their blood sample collected within 12 months from diagnosis yielded virtually identical results (data not shown).

In a joint analysis of stage and LTL, USKC cases with stage-I RCC and below-median (⩽0.85) LTL had significantly lower disease-specific survival than stage-I cases with LTL \>0.85 (HR: 5.5, 95% CI: 1.6--19.0; [Table 3](#tbl3){ref-type="table"}).

Discussion
==========

Our key finding, that shorter LTL is associated with poorer RCC disease-specific survival, is consistent with a prior study of 59 RCC cases with banked pre-diagnostic blood specimens and over 20 years of mortality follow-up, although the association in that study did not reach statistical significance ([@bib10]). Conversely, another study of 83 RCC cases including 22 deaths, using post-diagnostic samples, reported longer LTL to be associated with poorer prognosis; however, the association did not increase monotonically across quartiles of LTL ([@bib9]). Our study had a longer median follow-up time (USKC: 89 months PLCO: 168 months, *vs* 24 months) and a larger sample size than the study conducted by Svenson *et al*, which may, in part, explain our discordant findings. Interestingly, we found the association between LTL and survival to be strongest for stage-I RCC, which now accounts for most cases diagnosed in the United States ([@bib6]).

The biologic basis for the relationship between telomere length and RCC survival is unclear. LTL may be a surrogate for telomere length in the renal proximal tubule, as qPCR measurements in peripheral blood leukocytes and non-malignant renal tissue are moderately correlated ([@bib9]). Critically shortened telomeres in renal epithelium or tumour cells may, through consequent genetic instability, be contributing to tumour progression ([@bib2]). Alternatively, short telomeres may be associated with acceleration of senescence of immune cells, which could lead to a reduced immune response and poorer RCC survival. For instance, in a study of patients with colorectal cancer those with shorter LTL had a lower percentage of B cells and circulating TGF-*β*1 ([@bib1]). We note that aetiologic studies of LTL and RCC risk have yielded inconsistent findings ([@bib12]; [@bib8]; [@bib4], [@bib5]; [@bib10]). In particular, one prior study of pre-diagnosis LTL that investigated both RCC risk and survival observed suggestive evidence of an association only for the latter end point ([@bib10]). Considering the evidence to date, it is thus unclear whether the biologic effects underlying measured short LTL play a role in driving the development of this malignancy.

A potential limitation of this investigation is that LTL was measured by different laboratories using different standard reference DNA, which resulted in different summary measures of LTL. To account for this issue, we used study-specific cut points and analysed the studies separately. The retrospective and prospective designs of these two studies are complementary to one another when considering potential sources of bias. For example, a potential limitation of the USKC study is the use of blood collected after diagnosis, raising the possibility that LTL alterations may have been caused by the disease or treatment. Reverse causation bias is suspected to be responsible for the typically stronger LTL associations reported from studies using post-diagnostic samples *vs* prospective findings ([@bib11]). However, the confirmatory finding in PLCO cases, using pre-diagnostic blood, argues against such a bias. Conversely, the inability to adjust for stage and other clinical factors is a limitation of PLCO, while the USKC findings show the LTL-survival association is strengthened after adjustment for these factors ([Table 2](#tbl2){ref-type="table"}). Additional strengths of this investigation include its large size and the consistency in findings across studies.

Our observed association between short LTL and reduced RCC survival, particularly for stage-I disease, warrants replication in other study populations. If validated, this easily measured biomarker may have future clinical utility in staging of localised RCC.
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###### Characteristics of renal cell carcinoma patients from the US Kidney Cancer Study (USKC) and the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial included in LTL and disease-specific survival analyses

                                **USKC**      **PLCO**
  ----------------------------- ------------- -------------
  Age                                          
   ⩽59                          355 (51.9)    70 (29.0)
   60--64                       112 (16.4)    83 (34.4)
   65--69                       97 (14.2)     55 (22.8)
   ⩾70                          120 (17.5)    33 (13.7)
  Sex                                          
   Male                         390 (57.0)    169 (70.1)
   Female                       294 (43.0)    72 (29.9)
  Race                                         
   White                        525 (76.8)    214 (88.8)
   Black                        159 (23.2)    15 (6.2)
   Other                        0 (0.0)       12 (5.0)
  Smoking status                               
   Never                        281 (41.1)    96 (39.8)
   Past                         234 (34.2)    122 (50.6)
   Current                      169 (24.7)    23 (9.5)
  BMI (kg m^**−2**^)                           
   \<25                         133 (19.4)    49 (20.3)
   25--29.9                     239 (34.9)    101 (41.9)
   30--34.9                     169 (24.7)    65 (27.0)
   ⩾35                          143 (20.9)    26 (10.8)
  Subtype                                      
   Clear cell                   501 (73.2)     
   Papillary                    93 (13.6)      
   Chromophobe                  42 (6.1)       
   Cystic                       36 (5.3)       
   Other                        12 (1.8)       
  Tumour size                                  
   ⩽4 cm                        352 (51.5)     
   4.1--7 cm                    184 (26.9)     
   \>7 cm                       148 (21.6)     
  Stage                                        
   I                            473 (69.2)     
   II                           82 (12.0)      
   III and IV                   129 (18.9)     
                                Mean (s.d.)   Mean (s.d.)
  Telomere length (T/S ratio)   0.9 (0.2)     1.4 (0.6)

###### Association between leukocyte telomere length (LTL) and disease-specific survival among renal cell carcinoma patients from the US Kidney Cancer Study (USKC) and the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial[a](#t2-fn1){ref-type="fn"}

                                         **Quartile of LTL**                                                                                                                                   
  ------------------------------------- --------------------- -------- --------------------- ----------------- --------------------- ----------------- --------------------- ----------------- --------------------
                                               **Q4**         **Q3**          **Q2**         **Q1**                                                                                            
  **Study**                              ***n*** **(event)**  **HR**    ***n*** **(event)**  **HR (95% CI)**    ***n*** **(event)**  **HR (95% CI)**    ***n*** **(event)**  **HR (95% CI)**    ***P***~**trend**~
  USKC                                                                                                                                                                                                   
   Model 1[b](#t2-fn2){ref-type="fn"}         171 (20)        1.0            171 (24)        1.3 (0.7--2.4)          171 (21)        1.1 (0.6--2.0)          171 (31)        1.7 (0.9--3.0)            0.13
   Model 2[c](#t2-fn3){ref-type="fn"}                         1.0                            1.5 (0.7--3.0)                          1.7 (0.8--3.5)                          2.3 (1.2--4.4)            0.02
  PLCO[d](#t2-fn4){ref-type="fn"}              60 (15)        1.0             60 (11)        1.0 (0.4--2.5)           57 (14)        2.0 (0.8--4.9)           64 (22)        2.4 (1.0--5.4)            0.04
   Years from blood draw                                                                                                                                                                                 
    ⩽6.5                                       27 (9)         1.0             19 (4)         0.6 (0.1--2.4)           32 (9)         1.9 (0.5--7.8)           29 (7)         1.4 (0.3--6.1)            0.75
    \>6.5                                      33 (6)         1.0             41 (7)         0.8 (0.2--3.0)           25 (5)         2.0 (0.4--10.5)          35 (15)        3.4 (0.9--13.2)           0.04
  Combined[e](#t2-fn5){ref-type="fn"}                         1.0                            1.2 (0.7--2.0)                          1.8 (1.1--3.0)                          2.3 (1.3--4.1)           0.002

Analyses were performed using study-specific Cox proportional hazards models, study-specific cut points for LTL were based on quartiles of all cases included in these analyses as follows: USKC: Q1⩽0.73, Q2 0.73--0.85, Q3 0.85--1.01, Q4\>1.01; PLCO Q1⩽1.00, Q2 1.00--1.21, Q3 1.21--1.55, Q4\>1.55.

USKC model 1 was adjusted for age, sex, race, hypertension, smoking status, body mass index, education, and source of DNA (buffy coat *vs* whole blood).

USKC model 2 was adjusted for age, sex, race, hypertension, smoking status, body mass index, education, source of DNA (buffy coat *vs* whole blood), histologic subtype (clear cell, papillary, chromophobe, cystic or other), tumour size (⩽4 cm, 4.1--7 cm, or \>7 cm), treatment (no surgery or adjuvant treatment, surgery only, adjuvant treatment only, or adjuvant treatment and surgery), grade (I, II, III, or missing) and stage (I, II, or III/IV).

PLCO models were adjusted for age, sex, race, hypertension, smoking status, body mass index, education, study center, and source of DNA (buffy coat *vs* other).

USKC Model 2 and PLCO were combined using random effects meta-analysis, no heterogeneity was observed for any quartile (*I*^2^=0.00%).

###### Association between leukocyte telomere length (LTL), stage, and disease-specific survival among renal cell carcinoma patients from the US Kidney Cancer Study (USKC)

  **Stage**   ***LTL***   **n (event)**    **HR**[a](#t3-fn1){ref-type="fn"} **(95% CI)**  **P**~**interaction**~[b](#t3-fn2){ref-type="fn"}
  ----------- ----------- --------------- ------------------------------------------------ ---------------------------------------------------
  I           \>0.85      225 (3)                               1.0                        0.01
  I           ⩽0.85       248 (18)                        5.5 (1.6--19.0)                   
  II          \>0.85      51 (13)                         7.4 (1.8--30.0)                   
  II          ⩽0.85       31 (9)                          9.0 (2.1--38.7)                   
  III/IV      \>0.85      66 (28)                         19.0 (5.2--68.9)                  
  III/IV      ⩽0.85       63 (25)                         16.8 (4.6--62.0)                  

Adjusted for age, sex, race, hypertension, smoking status, body mass index, education, source of DNA (buffy coat *vs* whole blood), histologic subtype (clear cell, papillary, chromophobe, cystic or other), tumour size (\<4 cm, 4.1--7 cm, or \>7 cm), grade (I, II, III, or missing).

Test of interaction between stage and LTL from Cox proportional hazard model of disease-specific survival.
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